OTC Markets OTCQB - Delayed Quote USD

Filament Health Corp. (FLHLF)

0.0220

0.0000

(0.00%)

At close: April 25 at 4:00:00 PM EDT

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PEX010, THE COMPANY'S BOTANICAL PSILOCYBIN DRUG CANDIDATE, IN OPIOID USE DISORDER

Filament Health Corp. (OTCQB:FLHLF) (CBOE:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that the United States Food and Drug Administration (FDA) has authorized a phase 2 clinical trial study of its lead drug candidate, PEX010, at the University of Pennsylvania. The trial will study the effects of psychedelic-assisted psychotherapy (PAP) in the treatment of opioid use disorder (OUD), and is funded by the Wellcome Leap,

CNW Group 18 days ago

FLHLF
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Advanced Flower injected $14 million to fuel Standard Wellness expansion across key U.S. markets Organigram expanded into U.S. hemp-derived THC market with acquisition of Collective Project Vext exited Kentucky medical marijuana market to refocus on core states Innovative Industrial is grappling with tenant defaults, as the company faces a tough road […]

Market Exclusive 20 days ago

FLHLF
0.00%
AFCG

OGI
FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT AND INTENTION TO VOLUNTARILY DELIST FROM CBOE CANADA

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces a financing led by Negev Capital Fund One, LP ("Negev"), a leading psychedelic drug development venture fund and existing investor in the Company, Benjamin Lightburn, the Chairman of the Board, Chief Executive Officer and Co-Founder of the Company, and Michael Messinger, a member of the Board (the "Financing"). The Company exp

CNW Group 23 days ago

FLHLF
0.00%
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2024.

CNW Group 25 days ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF PEX010 IN PATIENTS WITH ALCOHOL USE DISORDER

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced positive data from an open-label phase 2 clinical trial studying the effects of its botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (AUD) at Psychiatric Centre Copenhagen. The results were published in the Journal of Psychopharmacology and found that a single 25mg dose of PEX010 was safe and

CNW Group last month

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has shipped its botanical psilocybin drug candidate, PEX010, to the University of Wisconsin–Madison (UW–Madison) for investigation in two clinical trials. Both trials are United States Food and Drug Administration (FDA)-authorized and will study the effects of psilocybin on neuroplasticity.

CNW Group 3 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences ("Magdalena"), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) ("Jaguar Health"), successfully completed an import of six kilograms of coca leaf from Peru to Filament's Metro Vancouver research and development facility. This is the second import of coca leaf that Magdale

CNW Group 4 months ago

FLHLF
0.00%
JAGX
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2024.

CNW Group 5 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that, it has issued 5,600,000 common shares in the capital of the Company (the "Common Shares") at a price of $0.05 per Common Share to Filament Health SPV – Allocations Funds LLC, Bioconnect Ventures – Allocations Funds LLC, and Sovereign74, LLC. The Common Shares are being issued to pursuant to an advisory agreement (the "Ad

CNW Group 6 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024.

CNW Group 8 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has expanded its intellectual property (IP) portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs. Filament has been issued a further five patents by the Canadian Intellectual Property Office (CIPO), and three patents by the United State

CNW Group 8 months ago

FLHLF
0.00%
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the "Common Shares") from the conversion of a convertible note due July 13, 2024 ("Note") and the exercise of the Acquiror's outstanding warrants ("Warrants") to purchase Common Shares (collectively, the "Transaction"). In connection with the Transact

Newsfile 10 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announces that, further to its press release dated June 3, 2024, it has completed its previously announced C$1.0 million bridge financing (the "Financing").

CNW Group 10 months ago

FLHLF
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6-10-24

Key Takeaways; Cannabis Sector Canopy Growth to fully acquire Acreage Holdings in strategic move AFC Gamma exited its largest portfolio loan, securing 19.9% return. Green Thumb CEO confirmed proposal to Boston Beer. Scotts Miracle-Gro adjusted financial outlook for 2024 but maintained strategic goals. Key Takeaways; Psychedelic Sector Filament Health received FDA approval for a meth […]

Market Exclusive 10 months ago

CGC

FLHLF
0.00%
AFCG
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced Health Canada and the United States Food and Drug Administration ("FDA") authorization for a Phase 2 clinical trial of PEX010, Filament's botanical psilocybin drug candidate, for the treatment of methamphetamine use disorder ("MAUD"). This will be the first ever clinical trial to study the safety and efficacy of botanical psilo

CNW Group 10 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has entered into agreements with Negev Capital Fund One, LP ("Negev"), a leading psychedelic drug development venture fund and existing investor in the Company, and Benjamin Lightburn, the Chief Executive Officer and Co-Founder of the Company, to complete a C$1.0 million bridge financing (the "Financing").

CNW Group 10 months ago

FLHLF
0.00%
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments ...

ACCESS Newswire 10 months ago

FLHLF
0.00%
JAGX
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024.

CNW Group 11 months ago

FLHLF
0.00%
FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024.

CNW Group 11 months ago

FLHLF
0.00%

Performance Overview

Return	FLHLF	MSCI WORLD (^990100-USD-STRD)
YTD	-44.72%	-2.41%
1-Year	-35.95%	+8.50%
3-Year	-87.77%	+28.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Filament Health Corp. (FLHLF)

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PEX010, THE COMPANY'S BOTANICAL PSILOCYBIN DRUG CANDIDATE, IN OPIOID USE DISORDER

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT AND INTENTION TO VOLUNTARILY DELIST FROM CBOE CANADA

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF PEX010 IN PATIENTS WITH ALCOHOL USE DISORDER

FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6-10-24

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Performance Overview